## Carboplatin

**Essential medicine status**

<table>
<thead>
<tr>
<th>Section</th>
<th>8. Immunomodulators and antineoplastics</th>
<th>8.2. Antineoplastics and supportive medicines</th>
<th>8.2.1. Cytotoxic medicines</th>
</tr>
</thead>
</table>

**ATC codes:** L01XA02

### Indication

Malignant neoplasms of nasopharynx

**ICD11 code:** 2C3B.Z

### INN

Carboplatin

### Medicine type

Chemical agent

### List type

Complementary

### Formulations

Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

### EML status history

- First added in 2009 (TRS 958)
- Changed in 2015 (TRS 994)

### Sex

All

### Age

Adolescents and adults

### Therapeutic alternatives

The recommendation is for this specific medicine

### Patent information

- Patents have expired in most jurisdictions
  - Read more [about patents](#)

### Tags

- Cancer

### Wikipedia

Carboplatin

### DrugBank

Carboplatin

---

**Summary of evidence and Expert Committee recommendations**

Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee’s consideration of treatment protocols for nasopharyngeal cancer is attached.